Takeover announcements give Monday’s US stock watchlist an unusually busy start. Marvell and Lumentum have agreed to combine, Perion has signed a cash acquisition agreement, and EVgo has received a buyout proposal. Apple and Palantir bring another set of catalysts after the closing bell, while regulatory developments put biotechnology shares in focus.
| Stock | Early Monday premarket move |
|---|---|
| Okta | +3.1% |
| Palantir | +1.2% |
| Apple | −0.4% |
Premarket changes are snapshots against Friday’s close.
In Simple Words
A company’s shares can move because of a takeover, a regulatory decision or an earnings announcement, even when the broader market is quiet. The details matter: a signed cash deal, an initial proposal and an agreement paid in shares each carry different implications.
Marvell: A huge acquisition puts AI connectivity at the centre
Marvell Technology (MRVL) has agreed to acquire Lumentum in an all-stock transaction with an implied enterprise value of approximately $115 billion. The combination brings Marvell’s electrical connectivity technology together with Lumentum’s optical components.
Also Read: US Top Earnings Today, November 2, 2026: Marriott, Estée Lauder, Fox and More
The commercial argument is faster, more closely integrated connections inside AI infrastructure. For Marvell shareholders, the immediate questions concern the shares being issued, the integration workload and the delivery of projected savings. Management expects annual cost synergies exceeding $1 billion.
| Transaction measure | Announced terms |
|---|---|
| Implied enterprise value | Approximately $115 billion |
| Expected annual cost synergies | More than $1 billion |
| Expected completion | First half of 2028 |
The transaction requires shareholder and regulatory approvals.
Lumentum: The exchange ratio becomes the key number
Lumentum (LITE) shareholders would receive a fixed number of Marvell shares for each share they own. That makes Marvell’s share price central to the changing market value of the offer.
Lumentum holders would retain exposure to the combined business rather than receive a cash exit. The lengthy timetable also makes the approval process important to how the shares trade.
Also Read: US Weekly Earnings Review: Microsoft, Alphabet, Amazon, Intel and Major Q3 Results (Oct 26–30, 2026)
| Shareholder terms | Announced figure |
|---|---|
| Marvell shares per Lumentum share | 4.5 |
| Lumentum holders’ combined-company ownership | Approximately 33% |
| Marvell holders’ combined-company ownership | Approximately 67% |
These ownership figures are stated on a fully diluted basis.
EVgo: LS Power submits a cash buyout proposal
EVgo (EVGO) has received a proposal from LS Power to acquire the outstanding Class A shares it does not already own. The proposal was delivered to the charging-network operator’s board on Monday.
The distinction between a proposal and an agreed transaction matters here. LS Power has reserved the right to change or withdraw its approach, leaving the board’s response and any subsequent agreement as the next substantive developments.
| Proposal detail | Terms |
|---|---|
| Proposed consideration | $2.00 per share |
| Payment | Cash |
| Shares targeted | Class A shares not owned by LS Power |
The filing provides no assurance that a transaction will be completed.
Also Read: US Stock Market Weekly Wrap-Up: AI Doubts Pull Wall Street Lower (Oct 26–30, 2026)
Perion: A signed takeover agreement changes the valuation debate
Perion Network (PERI) enters Monday following Sunday’s announcement of a definitive cash acquisition agreement with Affle. The Nasdaq-listed advertising technology company would become a wholly owned subsidiary and continue operating under its existing brand.
The signed agreement gives shareholders a specific cash consideration to assess. Perion can also solicit competing proposals during a defined go-shop period, while completion remains subject to shareholder approval and other closing conditions.
| Transaction measure | Announced terms |
|---|---|
| Cash consideration | $11.70 per share |
| Implied equity value | Approximately $420 million |
| Premium to Friday’s close | 34.5% |
| Expected completion | Early 2027 |
The agreement also includes a go-shop period ending in December.
Okta: Index inclusion creates a fresh demand catalyst
Okta (OKTA) is set to join the S&P 500, replacing Kenvue. The change was announced after Friday’s regular session, making Monday the first full trading day for investors to respond.
Also Read: US Stocks to Watch Today, October 30: Amazon, Intel and Rivian in Focus
Index inclusion matters because funds tracking the benchmark must reflect its membership. That creates a concrete ownership catalyst for the identity-security company, separate from changes in its operating performance.
| Index change | Details |
|---|---|
| Incoming company | Okta |
| Outgoing company | Kenvue |
| Effective date | Before trading on November 4 |
The approaching effective date puts portfolio adjustments in focus.
Inovio: Approval shifts attention towards commercial execution
Inovio Pharmaceuticals (INO) is in focus following accelerated approval of VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. The company scheduled a Monday morning conference call to discuss the approval and commercialisation.
The next stage is getting the treatment to patients. Inovio expects initial availability ahead of its broader launch, while continued approval may depend on confirmation of clinical benefit in further studies.
Also Read: Top US Earnings Today, October 29, 2026: Lilly, Mastercard, Caterpillar, Merck, Quanta and More
| Commercial milestone | Company timetable |
|---|---|
| Initial ordering and shipping | Approximately 60 days after approval |
| Full commercial launch | First quarter of 2027 |
| Regulatory pathway | Accelerated approval |
That moves the discussion from regulatory clearance towards launch preparation, physician adoption and the required confirmatory work.
uniQure: Priority review establishes a regulatory timetable
uniQure (QURE) announced Monday that the FDA accepted its application for an investigational Huntington’s disease gene therapy and granted priority review. The application seeks approval through the accelerated pathway.
Acceptance starts the formal review process; it does not constitute approval. The agency is tentatively planning an advisory committee discussion, while the company is preparing a confirmatory study.
| Regulatory milestone | Details |
|---|---|
| Target FDA action date | May 1, 2027 |
| Planned confirmatory-study enrolment | Approximately 200 patients |
| Planned US screening start | By the end of 2026 |
The review timetable and progress towards the confirmatory trial are now central stock-specific developments.
Also Read: Top US Market News Today, October 29, 2026: GDP Surge, DoorDash-Instacart Deal and Lagarde Exit
Apple: Tonight’s report puts the holiday outlook in focus
Apple (AAPL) reports its fiscal fourth-quarter results after Monday’s close. The announcement brings the holiday-quarter outlook, memory-chip costs and management’s comments on AI and Siri into focus.
The forward view carries particular weight. Investors will assess how product demand and component costs fit together, alongside the latest quarter’s performance. Monday also marks John Ternus’s first earnings call as chief executive.
| Scheduled event | Timing |
|---|---|
| Fiscal fourth-quarter results | After Monday’s close |
| Earnings conference call | 5:00 p.m. Eastern Time |
The call provides a direct opportunity for management to address those operating questions.
Palantir: An after-hours test for growth expectations
Palantir Technologies (PLTR) is scheduled to release its third-quarter results after the US market closes on Monday. That makes the upcoming announcement the immediate company-specific catalyst.
Also Read: Top US Earnings Today, October 28, 2026: GE Vernova, Vertiv, Biogen, Labcorp and More
The report will provide a fresh basis for assessing revenue momentum, profitability and management’s outlook. For the shares, the important comparison will be between what the business delivers and the expectations already reflected in its valuation.
| Scheduled announcement | Details |
|---|---|
| Reporting period | Third quarter of 2026 |
| Quarter ended | September 30, 2026 |
| Release timing | After Monday’s close |
The distinction between reported growth and the outlook for subsequent quarters will shape the response.
Vertex: Results bring acquisition accounting into view
Vertex Pharmaceuticals (VRTX) reports after Monday’s close, with its conference call scheduled shortly afterwards. Alongside the quarterly performance, management has committed to explaining the accounting and financial effects of its completed Crinetics acquisition.
That gives tonight’s announcement a specific additional purpose. The figures and commentary will help clarify how the acquired business fits into Vertex’s financial profile and its expansion into endocrine diseases.
Also Read: Top US Market News Today, October 28, 2026: Trade, Takeovers and AI Funding
| Scheduled event | Timing |
|---|---|
| Third-quarter results | After Monday’s close |
| Conference call | 4:30 p.m. Eastern Time |
| Additional focus | Crinetics acquisition’s financial impact |
The integration discussion will be an important companion to the headline results.
Disclaimer: This article is published for educational and informational purposes only and does not constitute financial, investment or trading advice. OneTrader is not registered with the Securities and Exchange Board of India (SEBI) as an investment adviser or research analyst. The information presented is not a recommendation to buy, sell or hold any security. Market conditions and company developments may change.
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.
Need a laugh after all that money talk?
Paisa LOL: India's funniest finance page, with memes, comics, jokes and long funny stories.
